These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 36689477)

  • 21. Molecular mechanism of Fufang Zhenzhu Tiaozhi capsule in the treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease based on network pharmacology and validation in minipigs.
    Wang H; Tan H; Zhan W; Song L; Zhang D; Chen X; Lin Z; Wang W; Yang Y; Wang L; Bei W; Guo J
    J Ethnopharmacol; 2021 Jun; 274():114056. PubMed ID: 33771638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. URAT1-selective inhibition ameliorates insulin resistance by attenuating diet-induced hepatic steatosis and brown adipose tissue whitening in mice.
    Tanaka Y; Nagoshi T; Takahashi H; Oi Y; Yoshii A; Kimura H; Ito K; Kashiwagi Y; Tanaka TD; Yoshimura M
    Mol Metab; 2022 Jan; 55():101411. PubMed ID: 34863940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatoprotective Effect of Seed Coat ofEuryale ferox Extract in Non-alcoholic Fatty Liver Disease Induced by High-fat Diet in Mice by Increasing IRs-1 and Inhibiting CYP2E1.
    Jian T; Yu C; Ding X; Chen J; Li J; Zuo Y; Ren B; Lv H; Li W
    J Oleo Sci; 2019 Jun; 68(6):581-589. PubMed ID: 31092797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans.
    Pafili K; Roden M
    Mol Metab; 2021 Aug; 50():101122. PubMed ID: 33220492
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
    Vassilatou E
    World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selenium and selenoprotein P in nonalcoholic fatty liver disease.
    Polyzos SA; Kountouras J; Goulas A; Duntas L
    Hormones (Athens); 2020 Mar; 19(1):61-72. PubMed ID: 31493247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relevant Aspects of Nutritional and Dietary Interventions in Non-Alcoholic Fatty Liver Disease.
    Hernandez-Rodas MC; Valenzuela R; Videla LA
    Int J Mol Sci; 2015 Oct; 16(10):25168-98. PubMed ID: 26512643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the active compounds and potential mechanism of the anti-nonalcoholic fatty liver disease activity of the fraction from Schisandra chinensis fruit extract based on multi-technology integrated network pharmacology.
    Li B; Xiao Q; Zhang J; Wang Y; Liu J; Zhang B; Liu H
    J Ethnopharmacol; 2023 Jan; 301():115769. PubMed ID: 36183952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural Compounds for Counteracting Nonalcoholic Fatty Liver Disease (NAFLD): Advantages and Limitations of the Suggested Candidates.
    Salvoza N; Giraudi PJ; Tiribelli C; Rosso N
    Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of vitamin E in nonalcoholic fatty liver disease.
    Nagashimada M; Ota T
    IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MiR-150 deficiency ameliorated hepatosteatosis and insulin resistance in nonalcoholic fatty liver disease via targeting CASP8 and FADD-like apoptosis regulator.
    Zhuge B; Li G
    Biochem Biophys Res Commun; 2017 Dec; 494(3-4):687-692. PubMed ID: 29107687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Review of the Effects of Fucoxanthin on NAFLD.
    Sayuti NH; Muhammad Nawawi KN; Goon JA; Mokhtar NM; Makpol S; Tan JK
    Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111187
    [TBL] [Abstract][Full Text] [Related]  

  • 34.
    Zandani G; Anavi-Cohen S; Yudelevich T; Nyska A; Dudai N; Madar Z; Gorelick J
    Nutrients; 2022 Oct; 14(21):. PubMed ID: 36364811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Salidroside and Curcumin Formula Prevents Liver Injury in Nonalcoholic Fatty Liver Disease in Rats.
    Li HS
    Ann Hepatol; 2018 Aug; 17(5):769-778. PubMed ID: 30145577
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling.
    Shabalala SC; Dludla PV; Mabasa L; Kappo AP; Basson AK; Pheiffer C; Johnson R
    Biomed Pharmacother; 2020 Nov; 131():110785. PubMed ID: 33152943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LPSF/GQ-02 inhibits the development of hepatic steatosis and inflammation in a mouse model of non-alcoholic fatty liver disease (NAFLD).
    Soares e Silva AK; de Oliveira Cipriano Torres D; dos Santos Gomes FO; dos Santos Silva B; Lima Ribeiro E; Costa Oliveira A; dos Santos LA; de Lima Mdo C; Pitta Ida R; Peixoto CA
    PLoS One; 2015; 10(4):e0123787. PubMed ID: 25875942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perilipin-2 promotes obesity and progressive fatty liver disease in mice through mechanistically distinct hepatocyte and extra-hepatocyte actions.
    Orlicky DJ; Libby AE; Bales ES; McMahan RH; Monks J; La Rosa FG; McManaman JL
    J Physiol; 2019 Mar; 597(6):1565-1584. PubMed ID: 30536914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease.
    Teng W; Zhao L; Yang S; Zhang C; Liu M; Luo J; Jin J; Zhang M; Bao C; Li D; Xiong W; Li Y; Ren F
    J Control Release; 2019 Aug; 307():139-149. PubMed ID: 31233775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.